Per Artikel

Riset dan Pengabdian Masyarakat Do Research Sosial Service and Innovation

Id	Authors	Author S Id	Title	Year	Source Title	Volume	Issue	Art No	Page Start	Page End	Link	Affiliations	Authors With Affiliations	Abstract	Author Keywords	Index Keywords	Publisher	Issn	Pubmed Id	Document Type	Sjr Best Quartile	Sjr	Sjr Rank
Display # Page 13 of 93 Start Prev 8 9 10 11 12 13 14 15 16 17 Next End
No records
121	Sutojo B., Irdam G.A.	57218247988;57194729795;	Safety of augmentation cystoplasty in patients with bladder abnormalities undergoing renal transplantation: A systematic review	2021	Medical Journal of Indonesia	30	3		198	206	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118766468&doi=10.13181%2fmji.oa.204358&partnerID=40&md5=c0ca75b4e475d11f04014befaa03201a	Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia	Sutojo, B., Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Irdam, G.A., Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia	BACKGROUND Augmentation cystoplasty (AC) has been recently proposed to improve a bladder condition before or after a renal transplantation for an optimal allograft function. Until now, AC in adults with end-stage renal disease (ESRD) is uncommon and rarely practiced. This study aimed to investigate the safety of AC in patients with bladder abnormalities who required renal transplantation. METHODS Studies of patients with ESRD and abnormal bladder who underwent AC were searched in ProQuest, PubMed, EBSCO, and Cochrane Library online databases. Only studies published in English from January 1985 to May 2020 were included. The keywords used were renal transplantation, bladder dysfunction, cystoplasty, and their synonyms. Data were extracted by two independent authors who selected, screened, and assessed the articles’ eligibility and quality. The outcomes were graft survival rate and complications of AC. RESULTS A total of 19 articles were included. AC improved an intravesical pressure, a bladder capacity, and a compliance in patients with ESRD and bladder abnormalities, allowing patients to undergo the renal transplantation. Even though AC in patients with renal transplantation resulted in a significantly higher urinary tract infection rate than patients who underwent renal transplantation only, performing AC after renal transplantation was considered safe. CONCLUSIONS AC was considered safe for patients with bladder abnormalities who underwent renal transplantation. © 2021, Faculty of Medicine, Universitas Indonesia. All rights reserved.	Cystoplasty; Efficacy; Renal transplantation; Safety	Article; bladder pressure; bladder reconstruction; bladder rupture; colonoscopy; graft survival; kidney transplantation; nephrolithiasis; nonhuman; systematic review; ureter obstruction; urinary tract infection; urodynamics; urolithiasis; vesicoureteral reflux; wound healing	Faculty of Medicine, Universitas Indonesia	08531773		Article	Q4	164	21905	View
122	Panigoro S.S., Sutandyo N., Witjaksono F., Siregar N.C., Ramli R., Hariani R., Pangarsa E.A., Prajoko Y.W., Puruhita N., Hamdani W., Bayu D., Madjid M., Yulidar D., Fransiska J.E., Widyawati R., Tripriadi E.S., Wiwit Ade F.W., Yunda D.K., Pranata R.	56790104300;26028099200;57070455800;6508087790;56126010900;57211658330;57204907532;56050815500;57224902090;57211471316;57193199487;57311861300;57312306100;57197735128;57312525600;57312968000;57312306200;57312748700;57201973901;	The Association Between Triglyceride-Glucose Index as a Marker of Insulin Resistance and the Risk of Breast Cancer	2021	Frontiers in Endocrinology	12		745236			https://www.scopus.com/inward/record.uri?eid=2-s2.0-85117891585&doi=10.3389%2ffendo.2021.745236&partnerID=40&md5=7c6ce4b0ece5dc9224c11aab644ae33c	Department of Surgical Oncology, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Hematology and Medical Oncology, Dharmais Hospital National Cancer Center, Jakarta, Indonesia; Department of Nutrition, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Pathological Anatomy, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Surgical Oncology, Dharmais Hospital National Cancer Center, Jakarta, Indonesia; Department of Nutrition, Dharmais Hospital National Cancer Center, Jakarta, Indonesia; Department of Hematology and Medical Oncology, Dr. Kariadi General Hospital, Faculty of Medicine, Diponegoro University, Semarang, Indonesia; Department of Surgical Oncology, Dr. Kariadi General Hospital, Faculty of Medicine, Diponegoro University, Semarang, Indonesia; Department of Nutrition, Dr. Kariadi General Hospital, Faculty of Medicine, Diponegoro University, Semarang, Indonesia; Department of Surgical Oncology, Wahidin Sudirohusodo General Hospital, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia; Division of Hematology-Medical Oncology, Department of Internal Medicine, Hasanuddin University General Hospital, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia; Department of Nutrition, Faculty of Medicine, Wahidin Sudirohusodo General Hospital, Hasanuddin University, Makassar, Indonesia; Department of Surgical Oncology, Dr. WZ Johannes General Hospital, Kupang, Indonesia; Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. WZ Johannes General Hospital, Kupang, Indonesia; Department of Pathological Anatomy, Dr. WZ Johannes General Hospital, Kupang, Indonesia; Department of Surgical Oncology, Arifin Achmad General Hospital, Faculty of Medicine, Riau University, Pekanbaru, Indonesia; Department of Pathological Anatomy, Arifin Achmad General Hospital, Faculty of Medicine, Riau University, Pekanbaru, Indonesia; Department of Nutrition, Arifin Achmad General Hospital, Faculty of Medicine, Riau University, Pekanbaru, Indonesia; Department of Nutrition, Nutrition Cancer Reaserch Team, Dharmais Hospital National Cancer Center, Jakarta, Indonesia	Panigoro, S.S., Department of Surgical Oncology, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sutandyo, N., Department of Hematology and Medical Oncology, Dharmais Hospital National Cancer Center, Jakarta, Indonesia; Witjaksono, F., Department of Nutrition, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Siregar, N.C., Department of Pathological Anatomy, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Ramli, R., Department of Surgical Oncology, Dharmais Hospital National Cancer Center, Jakarta, Indonesia; Hariani, R., Department of Nutrition, Dharmais Hospital National Cancer Center, Jakarta, Indonesia; Pangarsa, E.A., Department of Hematology and Medical Oncology, Dr. Kariadi General Hospital, Faculty of Medicine, Diponegoro University, Semarang, Indonesia; Prajoko, Y.W., Department of Surgical Oncology, Dr. Kariadi General Hospital, Faculty of Medicine, Diponegoro University, Semarang, Indonesia; Puruhita, N., Department of Nutrition, Dr. Kariadi General Hospital, Faculty of Medicine, Diponegoro University, Semarang, Indonesia; Hamdani, W., Department of Surgical Oncology, Wahidin Sudirohusodo General Hospital, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia; Bayu, D., Division of Hematology-Medical Oncology, Department of Internal Medicine, Hasanuddin University General Hospital, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia; Madjid, M., Department of Nutrition, Faculty of Medicine, Wahidin Sudirohusodo General Hospital, Hasanuddin University, Makassar, Indonesia; Yulidar, D., Department of Surgical Oncology, Dr. WZ Johannes General Hospital, Kupang, Indonesia; Fransiska, J.E., Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. WZ Johannes General Hospital, Kupang, Indonesia; Widyawati, R., Department of Pathological Anatomy, Dr. WZ Johannes General Hospital, Kupang, Indonesia; Tripriadi, E.S., Department of Surgical Oncology, Arifin Achmad General Hospital, Faculty of Medicine, Riau University, Pekanbaru, Indonesia; Wiwit Ade, F.W., Department of Pathological Anatomy, Arifin Achmad General Hospital, Faculty of Medicine, Riau University, Pekanbaru, Indonesia; Yunda, D.K., Department of Nutrition, Arifin Achmad General Hospital, Faculty of Medicine, Riau University, Pekanbaru, Indonesia; Pranata, R., Department of Nutrition, Nutrition Cancer Reaserch Team, Dharmais Hospital National Cancer Center, Jakarta, Indonesia	Background: This study aims to evaluate the association and dose-response between triglyceride-glucose (TyG) index and breast cancer. Method: This is a multicenter case-control study conducted in six public referral hospitals in Indonesia. Cases are individuals aged 19 years or above who were diagnosed with breast cancer within 1 year of diagnosis, based on histopathology and immunohistochemistry. Controls were recruited from corresponding hospitals. TyG index was determined by the formula: ln (fasting TG [mg/dl] × fasting glucose [mg/dl]). Results: There were 212 participants in the breast cancer group and 212 participants in the control group. TyG index was higher in patients with breast cancer (median 8.65 [7.38, 10.9] vs. 8.30 [7.09, 10.84], p < 0.001). When compared with TyG quartile of Q1, Q4 was associated with an OR of 2.42 (1.77, 3.31), p < 0.001, Q3 was associated with an OR of 1.53 (1.21, 1.93), p < 0.001, Q2 was associated with an OR of 1.39 (1.12, 1.73), p = 0.002 for the risk of breast cancer. The dose-response relationship was nonlinear (p < 0.001). On univariate analysis, smoking (OR 2.15 [1.44, 3.22], p < 0.001), use of contraception (1.73 [1.15, 2.60], p = 0.008), alcohol consumption (OR 2.04 [0.96, 4.35], p = 0.064), and TyG Index >8.87 (OR 3.08 [1.93, 4.93], p < 0.001) were associated with risk of breast cancer. Independently associated with increased risk of breast cancer included smoking (OR 1.93 [1.23, 3.01], p = 0.004), use of contraception (OR 1.59 [1.02, 2.48], p = 0.039), and TyG Index >8.87 (OR 2.93 [1.72, 4.98], p < 0.001) Conclusion: TyG index was associated with breast cancer in a nonlinear dose-response fashion. © Copyright © 2021 Panigoro, Sutandyo, Witjaksono, Siregar, Ramli, Hariani, Pangarsa, Prajoko, Puruhita, Hamdani, Bayu, Madjid, Yulidar, Fransiska, Widyawati, Tripriadi, F. W., Yunda and Pranata.	breast cancer; glucose; insulin; insulin resistance; triglyceride	insulin; triacylglycerol; adult; aged; alcohol consumption; Article; breast cancer; breast feeding; case control study; contraception; controlled study; dose response; female; glucose blood level; histopathology; human; human tissue; immunohistochemistry; major clinical study; multicenter study; nutrient uptake; obesity; questionnaire; smoking; triacylglycerol blood level; underweight; univariate analysis	Frontiers Media S.A.	16642392		Article	Q1	1518	2233	View
123	Hapsari P.W., Februhartanty J., Bardosono S.	57211782261;54962283200;21933841000;	Students’ interests and learning venues as enablers for school-based nutrition education among adolescents in Jakarta	2021	Nutrition and Food Science	51	8		1245	1257	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107899113&doi=10.1108%2fNFS-12-2020-0475&partnerID=40&md5=b45b1711d6c37301cd7a37b8fbd2c4c5	Department of Nutrition, Faculty of Medicine, Universitas Indonesia – Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Southeast Asian Ministers of Education Organization Regional Centre for Food and Nutrition (SEAMEO RECFON)/Pusat Kajian Gizi Regional Universitas Indonesia, Jakarta, Indonesia; Department of Nutrition, Faculty of Medicine, Universitas Indonesia – Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Southeast Asian Ministers of Education Organization Regional Centre for Food and Nutrition (SEAMEO RECFON), Pusat Kajian Gizi Regional Universitas Indonesia, Department of Nutrition Science, Universitas Jenderal Soedirman, Jakarta, Purwokerto, Indonesia	Hapsari, P.W., Department of Nutrition, Faculty of Medicine, Universitas Indonesia – Cipto Mangunkusumo Hospital, Jakarta, Indonesia, Southeast Asian Ministers of Education Organization Regional Centre for Food and Nutrition (SEAMEO RECFON), Pusat Kajian Gizi Regional Universitas Indonesia, Department of Nutrition Science, Universitas Jenderal Soedirman, Jakarta, Purwokerto, Indonesia; Februhartanty, J., Southeast Asian Ministers of Education Organization Regional Centre for Food and Nutrition (SEAMEO RECFON)/Pusat Kajian Gizi Regional Universitas Indonesia, Jakarta, Indonesia; Bardosono, S., Department of Nutrition, Faculty of Medicine, Universitas Indonesia – Cipto Mangunkusumo Hospital, Jakarta, Indonesia	Purpose: This study aims to explore potential enablers for school-based nutrition education (SBNE) through adolescent students’ perceptions in Jakarta, Indonesia. Design/methodology/approach: The study conducted 15 focus group discussions (FGDs) with 6–8 students per group to gather the main data, supported by six in-depth interviews with junior high school officials and content analysis of selected schoolbooks among five schools. The FGDs were conducted to explore students’ interest in nutrition information and their exposure to nutrition education and learning experiences. To analyze the FGD responses, three steps were used: coding, categorizing and determining themes. Findings: Students’ interest in nutrition and potential learning venues for interactive nutrition education were potential enablers for SBNE. The students’ interest in nutrition information comprised eight topics, with some different patterns by gender. Nutrition information not represented in the school books included: food fads, women’s nutrition, halal-certified food establishments and cooking. To complement the nutrition information that was not provided in school books, student club activities and school special programs were suitable settings as potential learning venues for SBNE. Originality/value: This study is the first study exploring SBNE facilitators from students’ perspectives among adolescents in Jakarta. © 2021, Emerald Publishing Limited.	Adolescents; Indonesia; Nutrition education	adolescent; article; clinical article; content analysis; cooking; female; food fads; gender; human; human experiment; Indonesia; interview; learning; male; middle school; nutrition education; perception	Emerald Group Holdings Ltd.	00346659		Article	Q3	318	14272	View
124	Bartlett A.W., Sudjaritruk T., Mohamed T.J., Anugulruengkit S., Kumarasamy N., Phongsamart W., Ly P.S., Truong K.H., Van Nguyen L., Do V.C., Ounchanum P., Puthanakit T., Chokephaibulkit K., Lumbiganon P., Kurniati N., Nik Yusoff N.K., Wati D.K., Sohn A.H., Kariminia A.	56511395900;36538198800;46961185600;57209773680;7003549856;8885235300;9743902800;35811540200;54396225800;56732729400;57200558813;8071686900;7003974471;35564244800;36473260300;6504631866;55816676300;7006405275;6602745222;	Identification, Management, and Outcomes of Combination Antiretroviral Treatment Failure in Adolescents With Perinatal Human Immunodeficiency Virus Infection in Asia	2021	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	73	7		e1919	e1926	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118283335&doi=10.1093%2fcid%2fciaa872&partnerID=40&md5=7af8cf47bd95718a30d3277b5797f9ba	Kirby Institute, University of New South Wales, Sydney, Australia; Department of Pediatrics, Faculty of Medicine, Research Institute for Health Sciences, Chiang Mai UniversityChiang Mai, Thailand; Women and Children Hospital Kuala LumpurKuala Lumpur, Malaysia; Department of Pediatrics, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Chennai Antiviral Research and Treatment Clinical Research Site, VHS-Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India; Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, Thailand; National Centre for HIV/AIDS, Dermatology and Sexually Transmitted DiseasesPhnom Penh, Cambodia; Children's Hospital 1, Ho Chi Minh City, Viet Nam; National Hospital of PediatricsHanoi, Viet Nam; Children's Hospital 2, Ho Chi Minh City, Viet Nam; Chiangrai Prachanukroh HospitalChiang Rai, Thailand; Department of Pediatrics, Faculty of Medicine, Khon Kaen UniversityKhon Kaen, Thailand; Cipto Mangunkusumo-Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Hospital Raja Perempuan Zainab IIKelantan, Malaysia; Sanglah Hospital, Udayana UniversityBali, Indonesia; TREAT Asia, amfAR-the Foundation for AIDS ResearchBangkok, Thailand	Bartlett, A.W., Kirby Institute, University of New South Wales, Sydney, Australia; Sudjaritruk, T., Department of Pediatrics, Faculty of Medicine, Research Institute for Health Sciences, Chiang Mai UniversityChiang Mai, Thailand; Mohamed, T.J., Women and Children Hospital Kuala LumpurKuala Lumpur, Malaysia; Anugulruengkit, S., Department of Pediatrics, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand, Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Kumarasamy, N., Chennai Antiviral Research and Treatment Clinical Research Site, VHS-Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India; Phongsamart, W., Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, Thailand; Ly, P.S., National Centre for HIV/AIDS, Dermatology and Sexually Transmitted DiseasesPhnom Penh, Cambodia; Truong, K.H., Children's Hospital 1, Ho Chi Minh City, Viet Nam; Van Nguyen, L., National Hospital of PediatricsHanoi, Viet Nam; Do, V.C., Children's Hospital 2, Ho Chi Minh City, Viet Nam; Ounchanum, P., Chiangrai Prachanukroh HospitalChiang Rai, Thailand; Puthanakit, T., Department of Pediatrics, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand, Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Chokephaibulkit, K., Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, Thailand; Lumbiganon, P., Department of Pediatrics, Faculty of Medicine, Khon Kaen UniversityKhon Kaen, Thailand; Kurniati, N., Cipto Mangunkusumo-Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Nik Yusoff, N.K., Hospital Raja Perempuan Zainab IIKelantan, Malaysia; Wati, D.K., Sanglah Hospital, Udayana UniversityBali, Indonesia; Sohn, A.H., TREAT Asia, amfAR-the Foundation for AIDS ResearchBangkok, Thailand; Kariminia, A., Kirby Institute, University of New South Wales, Sydney, Australia	BACKGROUND: Combination antiretroviral therapy (cART) failure is a major threat to human immunodeficiency virus (HIV) programs, with implications for individual- and population-level outcomes. Adolescents with perinatally acquired HIV infection (PHIVA) should be a focus for treatment failure given their poorer outcomes compared to children and adults. METHODS: Data (2014-2018) from a regional cohort of Asian PHIVA who received at least 6 months of continuous cART were analyzed. Treatment failure was defined according to World Health Organization criteria. Descriptive analyses were used to report treatment failure and subsequent management and evaluate postfailure CD4 count and viral load trends. Kaplan-Meier survival analyses were used to compare the cumulative incidence of death and loss to follow-up (LTFU) by treatment failure status. RESULTS: A total 3196 PHIVA were included in the analysis with a median follow-up period of 3.0 years, of whom 230 (7.2%) had experienced 292 treatment failure events (161 virologic, 128 immunologic, 11 clinical) at a rate of 3.78 per 100 person-years. Of the 292 treatment failure events, 31 (10.6%) had a subsequent cART switch within 6 months, which resulted in better immunologic and virologic outcomes compared to those who did not switch cART. The 5-year cumulative incidence of death and LTFU following treatment failure was 18.5% compared to 10.1% without treatment failure. CONCLUSIONS: Improved implementation of virologic monitoring is required to realize the benefits of virologic determination of cART failure. There is a need to address issues related to accessibility to subsequent cART regimens, poor adherence limiting scope to switch regimens, and the role of antiretroviral resistance testing. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.	adolescent; antiretroviral therapy; HIV; treatment failure	anti human immunodeficiency virus agent; adolescent; adult; Asia; CD4 lymphocyte count; child; female; human; Human immunodeficiency virus infection; pregnancy; treatment failure; virus load; Adolescent; Adult; Anti-HIV Agents; Asia; CD4 Lymphocyte Count; Child; Female; HIV Infections; Humans; Pregnancy; Treatment Failure; Viral Load	NLM (Medline)	15376591	32589711	Article	Q1	3440	518	View
125	Hermansyah T.A., Ginanjar E., Putri V.H.	57428569000;23472616600;57428569100;	Elevation of Cardiac Biomarkers in COVID-19 As a Major Determinant for Mortality: A Systematic Review	2021	Acta medica Indonesiana	53	4		385	396	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123568570&partnerID=40&md5=0047595d5dd32380033c242e7c79fe4c	Faculty of Medicine Universitas IndonesiaJakarta, Indonesia	Hermansyah, T.A., Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Ginanjar, E.; Putri, V.H.	BACKGROUND: This study aimed to summarize the prognosis of Corona Virus Disease 2019 (COVID-19) patients with elevated troponin and N-terminal pro brain natriuretic peptide (NT-proBNP) levels and demonstrate the involvement of myocardial injury as a complication in COVID-19. METHODS: A systematic literature search was performed using several databases (PubMed, MEDLINE, PROQUEST and SCOPUS ) for studies published up to August 2020. Observational studies about the mortality outcome of COVID-19 patients who experienced cardiac injury, as defined by the elevation of serum levels of troponin, brain natriuretic peptide (BNP), with NT-proBNP or only BNP or only NT-proBNP, were included. In addition, a critical appraisal was conducted for all included studies using the Critical Appraisal for Prognostic Studies checklist published by the Centre for Evidence-Based Medicine by the University of Oxford. RESULTS: Seven retrospective observational studies fulfilled the inclusion criteria. This study found that there is a higher risk of death in COVID 19 patients with higher levels of troponin and NT-proBNP, indicating the importance of these biomarkers as determinant factors to predict in-hospital deaths. CONCLUSION: Based on the analysis, elevation of troponin and NT-proBNP levels plays an essential role in determining the patient prognosis because it is shown to be associated with in-hospital mortality. This also supports the involvement of myocardial injury as a prominent fatal complication in COVID-19.	BNP; COVID-19; myocardial injury; NT-proBNP; prognostic factors; troponin	biological marker; brain natriuretic peptide; peptide fragment; pro-brain natriuretic peptide (1-76); troponin; blood; human; mortality; observational study; prognosis; retrospective study; Biomarkers; COVID-19; Humans; Natriuretic Peptide, Brain; Observational Studies as Topic; Peptide Fragments; Prognosis; Retrospective Studies; SARS-CoV-2; Troponin	NLM (Medline)	01259326	35027485	Article	Q3	321	14162	View
126	Saldi S.R.F., Safitri E.D., Setiati S., Ranakusuma R.W., Marsigit J., Azwar M.K., Astuti P., Sari C.Y.I., Istanti R., Yulianti M., Rumende C.M., Yunihastuti E., Susilo A., Harimurti K., Liastuti L.D., Trimartani T., Restuti R.D., Syam A.F.	55201904000;57195934356;14325991900;57189729404;57218912589;57202798959;57436688300;57218292263;23496653300;57216405885;14325966300;57221273925;57217867079;23473513200;57204676441;57428529000;55261428300;8443384400;	Prognostic Scoring System for Mortality of Hospitalized COVID-19 Patients in Resource-Limited Settings: A Multicenter Study from COVID-19 Referral Hospitals	2021	Acta medica Indonesiana	53	4		407	415	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123568238&partnerID=40&md5=e5654832599ee37e6d1d6dad0e5cc30c	Clinical Epidemiology and Evidence-Based Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo HospitalJakarta, Indonesia	Saldi, S.R.F., Clinical Epidemiology and Evidence-Based Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo HospitalJakarta, Indonesia; Safitri, E.D.; Setiati, S.; Ranakusuma, R.W.; Marsigit, J.; Azwar, M.K.; Astuti, P.; Sari, C.Y.I.; Istanti, R.; Yulianti, M.; Rumende, C.M.; Yunihastuti, E.; Susilo, A.; Harimurti, K.; Liastuti, L.D.; Trimartani, T.; Restuti, R.D.; Syam, A.F.	BACKGROUND: Many studies identified the risk factors and prognostic factors related to in-hospital COVID-19 mortality using sophisticated laboratory tests. Cost and the availability of supporting blood tests may be problematic in resource-limited settings. This multicenter cohort study was conducted to assess the factors associated with mortality of COVID-19 patients aged 18 years and older, based on history taking, physical examination, and simple blood tests to be used in resource-limited settings. METHODS: The study was conducted between July 2020 and January 2021 in five COVID-19 referral hospitals in Indonesia. Among 1048 confirmed cases of COVID-19, 160 (15%) died during hospitalization. RESULTS: Multivariate analysis showed eight predictors of in-hospital mortality, namely increased age, chronic kidney disease, chronic obstructive pulmonary disease, fatigue, dyspnea, altered mental status, neutrophil-lymphocyte ratio (NLR) ≥ 5.8, and severe-critical condition. This scoring system had an Area-under-the-curve (AUC) of 84.7%. With cut-off score of 6, the sensitivity was 76.3% and the specificity was 78.2%. CONCLUSION: The result of this practical prognostic scoring system may be a guide to decision making of physicians and help in the education of family members related to the possible outcome.	COVID-19; mortality; predictive score; prognostic; resource-limited settings	clinical trial; comorbidity; health care planning; hospital; hospital mortality; human; mortality; multicenter study; patient referral; prognosis; retrospective study; sensitivity and specificity; Comorbidity; COVID-19; Health Resources; Hospital Mortality; Hospitals; Humans; Prognosis; Referral and Consultation; Retrospective Studies; SARS-CoV-2; Sensitivity and Specificity	NLM (Medline)	01259326	35027487	Article	Q3	321	14162	View
127	Yunihastuti E.	57221273925;	Prioritizing Health Care Workers Safety: The International Year of Health and Care Workers 2021	2021	Acta medica Indonesiana	53	4		371	373	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123567858&partnerID=40&md5=6b031d0156ba2c68eb828650dd45d00d	Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo HospitalJakarta, Indonesia	Yunihastuti, E., Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo HospitalJakarta, Indonesia	Healthcare workers pose a substantial risk of acquiring COVID-19 infection during their daily works. We have seen various conditions during the pandemic, such as limited adequate personal protective equipment (PPE), accurate diagnostic tests, lack of information regarding disease management, unsupportive work environment, and excessive workload, increased the number of HCWs-infected COVID-19. Compared to the general population, the risk of COVID-19 infection was several-fold higher in HCWs.Employers and health care workers both should share the responsibility to prevent occupationally acquired infections and avoid causing harm to patients by taking reasonable precautions to prevent vaccine-preventable disease transmission.This year, WHO has launched a year-long campaign under the theme -protect, invest, together'. It highlights the urgent need to invest in health care workers, not only during COVID-19. We need to ensure that all health care workers are supported, protected, motivated, and equipped to deliver safe health care at all times, to provide a high-quality standard of care to the patients.	COVID-19; healthcare workers; personal protective equipment; safety; vaccination	health care personnel; human; occupational health; pandemic; protective equipment; World Health Organization; COVID-19; Health Personnel; Humans; Occupational Health; Pandemics; Personal Protective Equipment; World Health Organization	NLM (Medline)	01259326	35027483	Article	Q3	321	14162	View
128	Fadrian F., Chen K., Kumalawati J., Rumende C.M., Shatri H., Nelwan E.J.	57268114000;57428620500;6504406695;14325966300;28767986500;14527452900;	The Validation of Drug Resistance in Pneumonia (DRIP) Score in Predicting Infections due to Drug-Resistant Pathogens in Community-acquired Pneumonia at Cipto Mangunkusumo Hospital, Jakarta, Indonesia	2021	Acta medica Indonesiana	53	4		416	422	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123567110&partnerID=40&md5=9488cfa84614808f64df6510f7925f6d	1. Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Indonesia. 2. Division of Tropical Medicine and Infectious Disease, Department of Internal Medicine, Faculty of Medicine, alas University - M. Djamil Hospital, Padang, Jakarta, Indonesia	Fadrian, F., 1. Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Indonesia. 2. Division of Tropical Medicine and Infectious Disease, Department of Internal Medicine, Faculty of Medicine, alas University - M. Djamil Hospital, Padang, Jakarta, Indonesia; Chen, K.; Kumalawati, J.; Rumende, C.M.; Shatri, H.; Nelwan, E.J.	BACKGROUND: The emergence of drug-resistant pathogens (DRP) in recent years possibly contributes to the common problems associated with community-acquired pneumonia. However, to predict the risk of the ailment, the DRIP score is mainly applied, although no validation study has been reported in Indonesia. Therefore, the score prediction accuracy in the population, patient characteristics and germ patterns appears indefinite, particularly for Cipto Mangunkusumo Hospital, Jakarta. The purpose of this study is to determine the DRIP performance as an instrument in predicting infections due to drug-resistant pathogens (DRP) in community-acquired pneumonia at Cipto Mangunkusumo Hospital. METHODS: This research employed a cross-sectional design, where the subjects were community-acquired pneumonia patients treated between January 2019 and June 2020. In addition, adequate medical records of the participants were obtained. The condition is defined as DRP when the sputum culture results show resistance to non-pseudomonal β-lactam antibiotics, macrolides, and respiratory fluoroquinolones. Furthermore, the score performance was analyzed by determining the calibration and discrimination values, using the Hosmer-Lemeshow test and AUROC, respectively. RESULTS: A total of 254 subjects were known to have satisfied the selection criteria. These participants were categorized into DRP and non-DRP groups, with 103 (40.6%) and 151 (59.4%) patients, correspondingly. The DRIP calibration analysis using the Hosmer-Lemeshow test obtained p-value = 0.001 (p <0.05), while an AUC value of 0.759 (CI 95%, 0.702-0.810) was derived from the ROC curve. However, at a score of ≥ 4, the DRIP showed sensitivity, specificity, positive and negative predictive values of 70.9, 92.7, 86.9, and 82.3%, respectively. CONCLUSION: The DRIP score demonstrated a significant performance in predicting infections due to DRP in community-acquired pneumonia.	community-acquired pneumonia; DRIP score; resistant pathogens		NLM (Medline)	01259326	35027488	Article	Q3	321	14162	View
129	Nelwan E.J., Guterres H., Pasaribu A.I., Shakinah S., Limato R., Widodo D.	14527452900;57223285438;57428543800;57428569400;57196224631;8231822900;	The Comparison of Point Prevalence Survey (PPS) and Gyssens Flowchart Approach on Antimicrobial Use Surveillance in Indonesian National Referral Hospital	2021	Acta medica Indonesiana	53	4		505	511	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123566730&partnerID=40&md5=0eb0821dbbca8a19666af97b0fdd062d	1. Division of Tropical and Infectious Disease, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Indonesia 2. Infection and Immunology Research Cluster, Indonesian Medical Research Institute Faculty of Medicine Universitas Indonesia, Indonesia 3. Member of Antimicrobial Resistance Control Cipto Mangunkusumo HospitalJakarta, Indonesia	Nelwan, E.J., 1. Division of Tropical and Infectious Disease, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Indonesia 2. Infection and Immunology Research Cluster, Indonesian Medical Research Institute Faculty of Medicine Universitas Indonesia, Indonesia 3. Member of Antimicrobial Resistance Control Cipto Mangunkusumo HospitalJakarta, Indonesia; Guterres, H.; Pasaribu, A.I.; Shakinah, S.; Limato, R.; Widodo, D.	The antimicrobial resistance (AMR) rate in Indonesia is steadily rising, despite the existing national action plan in 2014. In line with the Global Action Plan on AMR, proper surveillance on antimicrobial usage and resistance are needed. At present, antimicrobial surveillance (AMS) data in Indonesia is heterogeneous, fragmented, and localized. The common method of antimicrobial surveillance (AMS) in referral hospitals is by implementing Gyssens flowchart during Antimicrobial Resistance Control Program Committee clinical rounds. However, the recent method of AMS with Point Prevalence Survey (PPS) offers many advantages include its concise and simple protocol, large data collection, shorter required time, comprehensive data outcomes, real-time data, and standardized parameters. In low-middle income countries such as Indonesia with its restricted resources in AMS, PPS is superior compared to the 'traditional' hospital clinical round in generating representative and homogenous outcomes that can be compared to data from other centers worldwide.	antimicrobial; Gyssens Flowchart; Indonesia; Point Prevalence Survey		NLM (Medline)	01259326	35027501	Article	Q3	321	14162	View
130	Yulianti M., Johan C., Singh G., Tenda E.D., Herikurniawan H., Wijaya I.P.E.K.	57216405885;57428554200;57209127773;57189692101;57428567200;57221504958;	Effectiveness of Convalescent Plasma Therapy in Treating COVID-19: an Evidence-based Case Report	2021	Acta medica Indonesiana	53	4		497	504	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123566521&partnerID=40&md5=3ff22c5c237f932569b8171a1ff5221b	Department of Internal Medicine, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia	Yulianti, M., Department of Internal Medicine, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Johan, C.; Singh, G.; Tenda, E.D.; Herikurniawan, H.; Wijaya, I.P.E.K.	BACKGROUND: Convalescent plasma is a potentially beneficial, tolerable, and available additional treatment option for COVID-19. This study aims to evaluate whether the administration of convalescent plasma therapy leads to improved clinical outcomes in COVID-19 patients compared to standard medical therapy. METHODS: We conducted a search of Pubmed, Cochrane, and EBSCO for studies assessing the clinical question using inclusion and exclusion criteria. Selected studies were critically appraised, and the results were summarized. RESULTS: A meta-analysis of 10 randomized clinical trials (RCTs), an RCT, a case-control clinical study were selected and assessed. Only the case-control clinical study showed that convalescent plasma administration improved the clinical outcomes of patients with COVID-19, including all-cause mortality, hospital length of stay, and the need for mechanical ventilation. On the contrary, the other two studies of a higher level of evidence showed no significant clinical outcome improvement with convalescent plasma therapy. CONCLUSION: The effectiveness of convalescent plasma therapy in improving clinical outcomes of patients with COVID-19 was still inconclusive due to several study limitations and other possible causes.	convalescent plasma; coronavirus; COVID-19; SARS-CoV-2	artificial ventilation; human; meta analysis; passive immunization; randomized controlled trial (topic); therapy; treatment outcome; COVID-19; Humans; Immunization, Passive; Randomized Controlled Trials as Topic; Respiration, Artificial; SARS-CoV-2; Treatment Outcome	NLM (Medline)	01259326	35027500	Article	Q3	321	14162	View

Publikasi Scopus 926 artikel (Per 14 Maret 2022)